Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tariff System (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Keytruda (pembrolizumab) in the treatment of patients with esophageal, gastroesophageal junction, and gastric cancer, HER2+
- Coatoris (ezetimibe + atorvastatin) for the prevention of cardiovascular events in patients with coronary artery disease and acute coronary syndrome, and for the treatment of hypercholesterolemia
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
